Recent research showed that CHK1 is a key regulator of lung fibrosis and CHK1 inhibition is considered as a potential novel therapeutic option for idiopathic pulmonary fibrosis (Wu et al., 2022). This evidence concerns the gene CHEK1 and idiopathic pulmonary fibrosis.